A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
- Conditions
- BRCA 1 Gene MutationBRCA 2 Gene MutationBreast Neoplasms
- Interventions
- Drug: Physician's-ChoiceDrug: talazoparib
- Registration Number
- NCT01945775
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 431
- Histologically or cytologically confirmed carcinoma of the breast
- Locally advanced breast cancer that is not amenable to curative radiation or surgical cure and/or metastatic disease appropriate for systemic single cytotoxic chemotherapy
- Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation from Myriad Genetics or other laboratory approved by the Sponsor
- No more than 3 prior chemotherapy-inclusive regimens for locally advanced and/or metastatic disease (no limit on prior hormonal therapies or targeted anticancer therapies such as mechanistic target of rapamycin (mTOR) or CDK4/6 inhibitors, immune-oncology agents, tyrosine kinase inhibitors, or monoclonal antibodies against CTL4 or VEGF)
- Prior treatment with a taxane and/or anthracycline in the neoadjuvant, adjuvant, locally advanced, or metastatic setting unless medically contraindicated
- Have measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v.1.1
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
-
First-line locally advanced and/or metastatic breast cancer with no prior adjuvant chemotherapy unless the Investigator determines that one of the 4 cytotoxic chemotherapy agents in the control arm would otherwise be offered to the subject
-
Prior treatment with a PARP inhibitor (not including iniparib)
-
Not a candidate for treatment with at least 1 of the treatments of protocol-specific physician's choice (ie, capecitabine, eribulin, gemcitabine, vinorelbine)
-
Subjects who had objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease; subjects who received low-dose platinum therapy administered in combination with radiation therapy are not excluded
-
Subjects who have received platinum in the adjuvant or neoadjuvant setting are eligible; however, subjects may not have relapsed within 6 months of the last dose of prior platinum therapy
-
Cytotoxic chemotherapy within 14 days before randomization
-
Radiation or anti-hormonal therapy or other targeted anticancer therapy within 14 days before randomization
-
HER2 positive breast cancer
-
Active inflammatory breast cancer
-
CNS metastases
- Exception: Adequately treated brain metastases documented by baseline CT or MRI scan that has not progressed since previous scans and that does not require corticosteroids (except prednisone ≤ 5 mg/day or equivalent) for management of CNS symptoms. A repeat CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases.
- Subjects with leptomeningeal carcinomatosis are not permitted
-
Prior malignancy except for any of the following:
- Prior BRCA-associated cancer as long as there is no current evidence of the cancer
- Carcinoma in situ or non-melanoma skin cancer
- A cancer diagnosed and definitively treated ≥ 5 years before randomization with no subsequent evidence of recurrence
-
Known to be human immunodeficiency virus positive
-
Known active hepatitis C virus, or known active hepatitis B virus
-
Known hypersensitivity to any of the components of talazoparib
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Physician's-Choice Physician's-Choice Capecitabine, Eribulin, Gemcitabine or Vinorelbine talazoparib talazoparib Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months) IRF assessed PFS was defined as time (in months) from randomization until the date of first documented radiologic progressive disease per response evaluation criteria in solid tumors (RECIST) version 1.1 or death from any cause, whichever occurs first. As per RECIST v1.1, progression defined as 1) for target lesions: at least a 20% increase in the sum of target lesion measurements, compared to the smallest sum on study (including baseline), the absolute increase in the sum has to be at least 5 millimeter (mm); 2) for non-target lesions: unequivocal progression of non-target lesions, evaluated as a whole, such that it is clear that treatment has failed and disease is progressing, regardless of the status of the target lesions; 3) and/or appearance of one or more new lesions. The analysis was performed by Kaplan-Meier method.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) Baseline until death due to any cause or analysis cut-off, up to a maximum duration of 61.4 months OS was defined as the time (in months) from randomization to death due to any cause. If death was not observed at the time of study cut-off date or permanently lost to follow-up, OS was censored at the date the participant was last known to be alive on or before the study cut-off date, whichever was earlier. The analysis was performed by Kaplan-Meier method.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months An adverse events (AE) was any untoward medical occurrence (e.g., sign, symptom, illness, disease or injury) in a participant administered study drug or other protocol-imposed intervention, regardless of attribution. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug or the day before initiation of a new antineoplastic therapy or 30 days after the date of the last dose date of study drug, whichever occurred first, that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.
Number of Participants Taking At-least One Concomitant Medication Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months Any medication (other than study drug) which was administered to participants during study after first dose of study drug were considered as concomitant medications.
Percentage of Participants With Objective Response: Investigator Assessment Baseline until radiologic progressive disease or death due to any cause (up to a maximum duration of 36.9 months) Investigator assessed objective response was defined as the percentage of participants with a partial response (PR) or complete response (CR) as defined by RECIST v1.1. For target lesions: 1) CR: disappearance of all non-nodal target lesions. Target lymph nodes must reduce to less than 10 mm in short axis. 2) PR: At least a 30% decrease in the sum of diameters of target lesions, compared to the sum at baseline. For non-target lesions, CR: disappearance of all non-target lesions. Percentage of participants with objective response reported are based upon unconfirmed CR/PR.
Number of Participants With Grade 3 or 4 Post-baseline Toxicities in Laboratory Parameters: Hematology Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months. Toxicity grades were evaluated based on as National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03). NCI CTCAE v4.03 defined the severity grade as: grade 1 (mild), grade 2 (moderate), grade 3 (severe), grade 4 (potentially life threatening) and grade 5 (death related to AE) for each parameter. Key hematology parameters included hemoglobin (gram per liter \[g/L\]), leukocytes (10\^6 cells per liter), lymphocytes (10\^6 cells per liter), neutrophils (10\^6 cells per liter), and platelets (10\^9 cells per liter). Low value indicated lower values than the baseline values and high value indicated higher values than the baseline values. Only those categories in which at least 1 participant had data were reported.
Number of Participants With Grade 3 or 4 Post-baseline Toxicities in Laboratory Parameters: Chemistry Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months Toxicity grades were evaluated based on as NCI CTCAE v4.03. NCI CTCAE v4.03 defined the severity grade as: grade 1 (mild), grade 2 (moderate), grade 3 (severe) and grade 4 (potentially life threatening) and grade 5 (death related to AE) for each parameter. Key chemistry parameters included alanine aminotransferase (units per liter), alkaline phosphatase (units per liter), aspartate aminotransferase (units per liter) and bilirubin (micromole per liter). High value indicated higher values than the baseline values and low value indicated lower values than the baseline values. Only those categories in which at least 1 participant had data were reported.
Number of Participants With Potentially Clinically Significant Changes From Baseline in Vital Signs Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months Criteria for potentially clinically significant changes in vital signs included a) Systolic blood pressure: 1) absolute results (AB) greater than (\>) 180 millimeter of mercury (mmHg) and increase from baseline (IFB) greater than or equal to (\>=) 40 mmHg, 2) absolute results less than (\<) 90 mmHg and decrease from baseline (DFB) \>30 mmHg; b) Diastolic blood pressure: 1) absolute results \>110 mmHg and \>=30 mmHg increase from baseline, 2) absolute results \<50 mmHg and \>20 mmHg decrease from baseline 3) \>=20 mmHg increase from baseline; c) Heart rate: 1) absolute results\>120 beats per minute \[bpm\] and \>30 bpm increase from baseline, 2) absolute results \<50 bpm and \>20 bpm decrease from baseline and d) Weight: \>10 percent \[%\] decrease from baseline.
Trough Plasma Talazoparib Concentrations Predose on Day 1 of Cycle 2, 3 and 4 A predose PK sample was considered dose-compliant based on the following criteria: A participant must have received 21 consecutive days of 1 mg talazoparib without dosing interruption prior to sample collection; and the predose PK sample must have been collected 24 hours +/- 10 percent (2 hours and 24 minutes) after the previous day's dose and no more than 5 minutes (0.083 hours) after the administration of the dose on the day of PK sample collection.
Trial Locations
- Locations (270)
University of California Los Angeles
🇺🇸Los Angeles, California, United States
Los Angeles Hematology Oncology Medical Group
🇺🇸Los Angeles, California, United States
University of Maryland, Greenebaum Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Texas Oncology-Memorial City
🇺🇸Houston, Texas, United States
University Of Texas, Md Anderson Cancer Center
🇺🇸Houston, Texas, United States
UT MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Swedish Cancer Institute
🇺🇸Seattle, Washington, United States
Swedish Medical Center
🇺🇸Seattle, Washington, United States
The University of Kansas Cancer Center (Regulatory Office)
🇺🇸Fairway, Kansas, United States
Sir Charles Gairdner Hospital Lung Institute Of Western Australia
🇦🇺Nedlands, Western Australia, Australia
Arizona Oncology Associates P.C. - NAHOA
🇺🇸Flagstaff, Arizona, United States
Comprehensive Cancer Centers Of Nevada
🇺🇸Henderson, Nevada, United States
Radiologicum
🇩🇪Munich, Bavaria, Germany
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Oncology Institute, Rambam Health Care Campus
🇮🇱Haifa, Israel
Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola
🇵🇱Poznan, Poland
HonorHealth
🇺🇸Scottsdale, Arizona, United States
IOZ Muenchen
🇩🇪Munich, Bavaria, Germany
Assaf Harofeh Medical Center
🇮🇱Zerifin, Israel
Uniwersyteckie Centrum Kliniczne Klinika Onkologii i Radioterapii
🇵🇱Gdansk, Poland
Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie, Oddzial w Gliwicach
🇵🇱Gliwice, Poland
City Clinical Oncology Dispensary
🇷🇺St. Petersburg, Russian Federation
Cancer Center of Central Connecticut
🇺🇸Plainville, Connecticut, United States
Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden
🇩🇪Dresden, Saxony, Germany
Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Pozna
🇵🇱Poznan, Poland
Assuta Medical Center
🇮🇱Tel Aviv, Israel
Medizinisches Zentrum fur Hamatologie und Onkologie Munchen MVZ
🇩🇪Munich, Bavaria, Germany
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
University of Tennessee Medical Center
🇺🇸Knoxville, Tennessee, United States
Nova Pharmacy
🇦🇺Wendouree, Victoria, Australia
Ballarat Oncology & Haematology Services
🇦🇺Wendouree, Victoria, Australia
Mater Misericordiae University Hospital
🇮🇪Dublin 7, Ireland
Oncology Institute, Assuta Medical Center
🇮🇱Tel-Aviv, Israel
A.S.S.T. Monza
🇮🇹Monza, Monza AND Brianza, Italy
Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego
🇵🇱Poznan, Poland
Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej-Curie
🇵🇱Poznan, Poland
Pracownia Tomografii Komputerowej , Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie
🇵🇱Szczecin, Poland
State Budgetary Institution of Healthcare "Republican Oncology dispensary"'
🇷🇺Petrozavodsk, Russian Federation
Austin Health, The Austin Hospital
🇦🇺Melbourne, Victoria, Australia
Sarah Cannon Research Institute UK
🇬🇧London, England, United Kingdom
Soroka University Medical Center
🇮🇱Beer Sheva, Israel
The Chaim sheba Medical Center
🇮🇱Tel Hashomer, Israel
Uniwersyteckie Centrum Kliniczne, Zaklad Radiologii
🇵🇱Gdansk, Poland
NU-MED Centrum Diagnostyki i Terapii Onkologicznej Katowice
🇵🇱Katowice, Poland
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie Klinika Nowotworow Piersi i
🇵🇱Warszawa, Poland
Nottingham University Hospital NHS Trust
🇬🇧Nottingham, Nottinghamshire, United Kingdom
Drug Management Only: UCLA West Medical Pharmacy, Attn:Steven L. Wong, Pharm.D.
🇺🇸Los Angeles, California, United States
Virginia G. Piper Cancer Pharmacy
🇺🇸Scottsdale, Arizona, United States
Kaiser Permanente Medical Center Lab Drawing Station
🇺🇸San Jose, California, United States
Ronald Reagan UCLA Medical Center
🇺🇸Los Angeles, California, United States
Marin Specialty Care
🇺🇸Greenbrae, California, United States
Central Coast Medical Oncology Corporation
🇺🇸Santa Maria, California, United States
Ridley Tree Cancer Center
🇺🇸Solvang, California, United States
Sutter North Bay Health Plaza
🇺🇸Santa Rosa, California, United States
UCLA Hematology/Oncology - Parkside
🇺🇸Santa Monica, California, United States
Stanford Women's Cancer Center
🇺🇸Stanford, California, United States
UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm. D.
🇺🇸Los Angeles, California, United States
UCLA West Medical Pharmacy, Attn:Steven L. Wong, Pharm.D.
🇺🇸Los Angeles, California, United States
Rocky Mountain Cancer Centers
🇺🇸Thornton, Colorado, United States
Weill Cornell Medical College - New York Presbyterian Hospital
🇺🇸New York, New York, United States
Florida Cancer Specialists
🇺🇸Tavares, Florida, United States
The West Clinic, P.C. d/b/a West Cancer Center
🇺🇸Memphis, Tennessee, United States
Memorial Regional Hospital
🇺🇸Hollywood, Florida, United States
The University of Kansas Cancer Center - Investigational Drug Services
🇺🇸Westwood, Kansas, United States
Sylvester Comprehensive Cancer Center Deerfield Beach
🇺🇸Deerfield Beach, Florida, United States
UCLA Hematology/Oncology - Santa Clarita
🇺🇸Valencia, California, United States
Cancer Specialists of North Florida
🇺🇸Saint Augustine, Florida, United States
Santa Barbara Cottage Hospital
🇺🇸Santa Barbara, California, United States
UCLA Hematology Oncology
🇺🇸Santa Monica, California, United States
Oklahoma Cancer Specialists and Research Institute, LLC
🇺🇸Tulsa, Oklahoma, United States
Eastchester Center for Cancer Care
🇺🇸Bronx, New York, United States
Novant Health Matthews Medical Center
🇺🇸Matthews, North Carolina, United States
Perlmutter Cancer Center
🇺🇸New York, New York, United States
Stanford Cancer Institute
🇺🇸Stanford, California, United States
Novant Health Cancer Specialists
🇺🇸Matthews, North Carolina, United States
Hope Women's Cancer Centers
🇺🇸Asheville, North Carolina, United States
Weill Cornell Medical Center
🇺🇸New York, New York, United States
Minnesota Oncology Hematology, P.A.
🇺🇸Woodbury, Minnesota, United States
Magee-Womens Hospital of UPMC
🇺🇸Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center, William M. Cooper Pavilion, Hillman Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States
Central Georgia Cancer Care, PC
🇺🇸Warner Robins, Georgia, United States
New York Oncology Hematology, P.C.
🇺🇸Clifton Park, New York, United States
Cancer And Hematology Centers Of Western Michigan
🇺🇸Grand Rapids, Michigan, United States
Northwest Cancer Specialists, P.C.
🇺🇸Vancouver, Washington, United States
The West Clinic, P.C.
🇺🇸Corinth, Mississippi, United States
UPMC Hillman Cancer Center Erie
🇺🇸Erie, Pennsylvania, United States
Investigational Products Center (IPC)
🇺🇸Fort Worth, Texas, United States
Texas Oncology-Seton Williamson
🇺🇸Round Rock, Texas, United States
Texas Oncology - Waco
🇺🇸Waco, Texas, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
🇺🇸Dallas, Texas, United States
Texas Oncology - El Paso Cancer Treatment Center Joe Battle
🇺🇸El Paso, Texas, United States
Texas Oncology-Waco
🇺🇸Waco, Texas, United States
Virginia Oncology Associates
🇺🇸Virginia Beach, Virginia, United States
Icon Cancer Care South Brisbane
🇦🇺South Brisbane, Queensland, Australia
Peninsula & South Eastern Haematology and Oncology Group
🇦🇺Frankston, Victoria, Australia
Austin Health, Heidelberg Repatriation Hospital (radiology (MUGA)scans only)
🇦🇺Heidelberg West, Victoria, Australia
ICON Cancer Foundation
🇦🇺South Brisbane, Queensland, Australia
Adelaide Cancer Centre
🇦🇺Kurralta Park, South Australia, Australia
Ballarat Oncology & Haematology Services Clinical Trials Unit
🇦🇺Wendouree, Victoria, Australia
CHU Sart Tilman Liege
🇧🇪Liege, Belgium
A.O.S.G. Moscati - Contrada Amoretta
🇮🇹Avellino, AV, Italy
Ospedale S. Raffaelle di Milano
🇮🇹Milano, MI, Italy
Ospendale Sant'Andrea
🇮🇹Roma, RM, Italy
St. Vincent's University Hospital
🇮🇪Dublin 4, Ireland
Division of Oncology Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
La Maddalena Clinic For Cancer University Of Palermo
🇮🇹Palermo, PA, Italy
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia
Universitair Ziekenhuis Gent
🇧🇪Gent, Belgium
CHRU Jean Minjoz
🇫🇷Besancon, France
Central de Quimioterapia Hospital do Cancer-INCA-HCIII
🇧🇷Rio de Janeiro, RJ, Brazil
Hospital do Cancer III - INCA / Instituto Nacional do Cancer / MS INCA HCIII
🇧🇷Rio de Janeiro, RJ, Brazil
Ospedale Mater Salutis
🇮🇹Legnago, VR, Italy
National Cancer Centre
🇰🇷Goyang-si, Gyeonggi-do, Korea, Republic of
Oncologie Unter Ems
🇩🇪Leer, Germany
Universitaetsfrauenklinik
🇩🇪Ulm, Germany
Unifrauenklinik am Klinikum Suedstadt
🇩🇪Rostock, Germany
University Hospital Galway
🇮🇪Galway, Ireland
Oncology Institute, Davidoff Center, Rabin Medical Center, Beilinson Campus
🇮🇱Petach Tikva, Israel
A.S.S.T. Monza, Oncologia Medica, Ospedale San Gerardo
🇮🇹Monza, Monza Brianza, Italy
Senologia Medica, IRCCS-Instituto Oncologico Europeo (IEO)
🇮🇹Milano, Italy
Ewha Womans University Mokdong Hospital
🇰🇷Seoul, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
S.S.D. Oncologia Medica Addarii - A.O.U. di Bologna - Policlinico Sant'Orsola-Malpighi
🇮🇹Bologna, Italy
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Universita Campus Bio-Medico di Roma, Dipartimento Oncologia Medica
🇮🇹Roma, Italy
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
Ajou University Hospital
🇰🇷Suwon, Gyeonggi-do, Korea, Republic of
Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
🇵🇱Lodz, LODZ Province, Poland
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Uniwersyteckie Centrum Kliniczne, Zaklad Medycyny Nuklearnej
🇵🇱Gdansk, Poland
Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu
🇵🇱Katowice, Poland
Ulsan University Hospital
🇰🇷Ulsan, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Klinika Onkologii, Wojskowy lnstytut Medyczny
🇵🇱Warszawa, Poland
Gbuz Lood
🇷🇺Leningrad, Leningrad Region, Russian Federation
Complejo Hospitalario de Jaen
🇪🇸Jaen, Spain
Regional Municipal Institution "Sumy Regional Clinical Oncology Dispensary", Thoracic Department
🇺🇦Sumy, Ukraine
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Consorcio Hospitalario Provincial de Castellon
🇪🇸Castellon, Spain
Hospital Universitari Arnau de Vilanova de Lleida
🇪🇸Lleida, Spain
St James University Hospital
🇬🇧Leeds, United Kingdom
The University of Kansas Cancer Center
🇺🇸Lee's Summit, Missouri, United States
New York University Langone Medical Center
🇺🇸New York, New York, United States
New York-Presbyterian Hospital/Weill Cornell Medical Center
🇺🇸New York, New York, United States
Icon Cancer Care, Corporate Office
🇦🇺South Brisbane, Queensland, Australia
Ashford Cancer Centre Research
🇦🇺Kurralta Park, South Australia, Australia
River City Pharmacy
🇦🇺Auchenflower, Australia
Concord Repatriation General Hospital
🇦🇺Concord, New South Wales, Australia
Los Angeles Hematology Oncolgy Medical Group
🇺🇸Los Angeles, California, United States
Drug Management only: UCLA West Medical Pharmacy
🇺🇸Los Angeles, California, United States
UCLA West Medical Pharmacy, Attn: Steven L. Wong
🇺🇸Los Angeles, California, United States
Regulatory Managment Only: TRIO-US Central Administration
🇺🇸Los Angeles, California, United States
Kaiser Permanente Medical Center (clinic+DSL)
🇺🇸Walnut Creek, California, United States
Kaiser Permanente Medical Center (Radiology)
🇺🇸Oakland, California, United States
Southern California Permanente Medical Group
🇺🇸Woodland Hills, California, United States
Cancer Care SA trading as Icon Pharmacy Adelaide
🇦🇺Kurralta Park, South Australia, Australia
Klinikum rechts der Isar, TUM, Frauenklinik und Poliklinik
🇩🇪Munich, Germany
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
TRIO-US Central Administration
🇺🇸Los Angeles, California, United States
ICON Cancer Care (Haematology And Oncology Clinics Of Australasia (Hoca))-Milton
🇦🇺Milton, Queensland, Australia
Kaiser Permanente Mission Bay Medical Center Lab Drawing Station
🇺🇸San Francisco, California, United States
UCSF - Helen Diller Family Comprehensive Cancer Center
🇺🇸San Francisco, California, United States
UCSF Helen Diller Comprehensive Cancer Centre - Precision Cancer Medicine Building
🇺🇸San Francisco, California, United States
University of Colorado Cancer Center - Anschutz Cancer Pavilion (ACP)
🇺🇸Aurora, Colorado, United States
"University of Miami Hospital & Clinics,Sylvester Comprehensive Cancer Center/UMHC"
🇺🇸Miami, Florida, United States
Sylvester Comprehensive Cancer Center Kendall
🇺🇸Miami, Florida, United States
Orlando Health, Inc
🇺🇸Orlando, Florida, United States
Indiana University- Melvin and Bren Simon Cancer Center (IUSCC)
🇺🇸Indianapolis, Indiana, United States
IU Health University Hospital
🇺🇸Indianapolis, Indiana, United States
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States
Sidney and Lois Eskenazi Hospital
🇺🇸Indianapolis, Indiana, United States
Springmill Medical Clinic
🇺🇸Indianapolis, Indiana, United States
University of Michigan Health System
🇺🇸Ann Arbor, Michigan, United States
UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D.
🇺🇸Los Angeles, California, United States
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
🇺🇸Fullerton, California, United States
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
🇺🇸Bakersfield, California, United States
Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer care Associates
🇺🇸Redondo Beach, California, United States
Pacific Central Coast Health Centers - San Luis Obispo Oncology and Hematology Health Center
🇺🇸San Luis Obispo, California, United States
Sutter Santa Rosa Regional Hospital
🇺🇸Santa Rosa, California, United States
Sutter Pacific Medical Foundation
🇺🇸Santa Rosa, California, United States
Weill Cornell Breast Center
🇺🇸New York, New York, United States
Weill Cornell Medical College - New York-Presbyterian Hospital
🇺🇸New York, New York, United States
Sylvester Comprehensive Cancer Center Plantation
🇺🇸Plantation, Florida, United States
Novant Health Huntersville Medical Center
🇺🇸Huntersville, North Carolina, United States
Novant Health Presbyterian Medical Center
🇺🇸Charlotte, North Carolina, United States
Southern Oncology Specialists
🇺🇸Huntersville, North Carolina, United States
Lake Norman Hematology Oncology Specialists
🇺🇸Mooresville, North Carolina, United States
Texas Oncology-South Austin
🇺🇸Austin, Texas, United States
The Center for Cancer and Blood Disorders
🇺🇸Weatherford, Texas, United States
The Center for Cancer and Blood Disorders (Huguley)
🇺🇸Burleson, Texas, United States
Texas Oncology - Cedar Park
🇺🇸Cedar Park, Texas, United States
Texas Oncology-El Paso Cancer Treatment Center Gateway
🇺🇸El Paso, Texas, United States
US Oncology Investigational Products Center(IPC)
🇺🇸Irving, Texas, United States
Texas Oncology-Plano East
🇺🇸Plano, Texas, United States
US Oncology Investigational Product Center (IPC)
🇺🇸Irving, Texas, United States
US Oncology Investigational Products Center (IPC)
🇺🇸Irving, Texas, United States
Flinders Medical Centre
🇦🇺Bedford Park, South Australia, Australia
Cancer Care SA PTY Ltd
🇦🇺Kurralta Park, South Australia, Australia
Slade Pharmacy Mount Waverley
🇦🇺Mount Waverley, Victoria, Australia
Icon Cancer Care
🇦🇺Milton, Australia
Instituto Nacional do Cancer Jose de Alencar Gomes da Silva
🇧🇷Rio de Janeiro, RJ, Brazil
Hospital da Cidade de Passo Fundo - HCPF
🇧🇷Passo Fundo, RS, Brazil
Hospital de Clinicas de Porto Alegre
🇧🇷Porto Alegre, RS, Brazil
Hopital da Cidade de Passo Fundo
🇧🇷Passo Fundo, RS, Brazil
Associacao Hospitalar Moinhos de Vento
🇧🇷Porto Alegre, RS, Brazil
Uniao Brasileira de Educacao E Assistencia
🇧🇷Porto Alegre, RS, Brazil
Hospital do Cancer de Barretos - Fundacao Pio XII
🇧🇷Barretos, SP, Brazil
Fundacao Hospital Amaral Carvalho
🇧🇷Jau, SP, Brazil
Memorial Healthcare System
🇺🇸Hollywood, Florida, United States
Instituto de Oncologia de Piracicaba S/S Ltda.
🇧🇷Piracicaba, SP, Brazil
Centro de Referencia da Saude da Mulher - Hospital Perola Byington
🇧🇷Sao Paulo, SP, Brazil
Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecologica e Mamária Ltda.
🇧🇷Sao Paulo, SP, Brazil
Institut Paoli Calmettes
🇫🇷Marseille, France
Centre Leon Berard
🇫🇷LYON cedex 08, France
Hopital Prive du Confluent
🇫🇷Nantes BP 20215, France
Hopital Saint Louis
🇫🇷Paris, France
Hopital Tenon
🇫🇷Paris, France
Institut Universitaire du Cancer Toulouse - Oncopole
🇫🇷Toulouse, France
Institut de Cancerologie de l'Ouest - Site Rene Gauducheau
🇫🇷Saint Herblain, France
UCLA Santa Monica Medical Center & Orthopaedic Hospital
🇺🇸Santa Monica, California, United States
MH Mission Hospital, LLLP
🇺🇸Asheville, North Carolina, United States
Hopitaux Universitaires de Strasbourg - Hopital Civil
🇫🇷Strasbourg, France
Virginia Cancer Specialists, PC
🇺🇸Fairfax, Virginia, United States
CHU Bretonneau Centre Henry Kaplan
🇫🇷Tours Cedex 9, France
Institut Gustave Roussy
🇫🇷Villejuif Cedex, France
University of Munich (LMU), Grosshadern Hospital
🇩🇪Munich, Bavaria, Germany
University Hospital Duesseldorf
🇩🇪Duesseldorf, Germany
Praxisklinik Krebsheilkunde fuer Frauen/Brustzentrum
🇩🇪Berlin, Germany
HELIOS Klinikum Berlin-Buch
🇩🇪Berlin, Germany
Kliniken Essen-Mitte, Klinik für Senologie / Brustzentrum
🇩🇪Essen, Germany
Universitaetsklinikum Erlangen
🇩🇪Erlangen, Germany
Universitaetsklinikum Freiburg, Klinik fuer Frauenheilunde
🇩🇪Freiburg, Germany
A.O.U. Pisana, DAI Oncologia, U.O. Oncologia Med. 2 Univ.
🇮🇹Pisa, PI, Italy
Seoul National University Bundang Hospital
🇰🇷Bundang-gu, Gyeonggi-do, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
NZOZ Innowacyjna Medycyna
🇵🇱Dobra, Poland
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
🇵🇱Gdansk, Poland
Europejskie Centrum Zdrowia Otwock Szpital im.F.Chopina
🇵🇱Otwock, Poland
Oddzial Onkologii Klinicznej, Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie
🇵🇱Szczecin, Poland
Pracownia Medycyny Nuklearnej, 109 Szpital Wojskowy z Przychodnia SP ZOZ
🇵🇱Szczecin, Poland
Hospital Nuestra Senora de Sonsoles(Complejo Asistencial de Avila)
🇪🇸Avila, Spain
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona Barcelona, Spain
Hospital Clinic I Provincial
🇪🇸Barcelona, Spain
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital Universitario de Canarias
🇪🇸La Laguna Santa Cruz De Tenerife, Spain
Centro Oncologico de Galicia
🇪🇸La Coruna, Spain
Hospital Universitario de La Princesa
🇪🇸Madrid, Spain
Corporacio Sanitaria Parc Tauli
🇪🇸Sabadell Barcelona, Spain
Hospital General Universitario Gregorio Maranon
🇪🇸Madrid, Spain
Hospital Universitario Ramon Y Cajal
🇪🇸Madrid, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
Hospital Universitario Quiron Madrid
🇪🇸Pozuelo De Alarcon (Madrid), Spain
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Royal Sussex County Hospital, Royal Alexandra Children's Hospital L10
🇬🇧Brighton, United Kingdom
Communal Institution "Krivorizhskiy Oncology Dispensary" of Dnipropetrovsk Regional Council
🇺🇦Kriviy Rig, Ukraine
Impretial College Healthcare NHS Trust
🇬🇧London, United Kingdom
Cancer Research UK, Department of Medical Oncology - The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
Texas Oncology-El Paso Cancer Treatment Center Grandview
🇺🇸El Paso, Texas, United States
Northwest Cancer Specialists, P.C.(Admin Only)
🇺🇸Vancouver, Washington, United States
Tennessee Oncology, PLLC
🇺🇸Shelbyville, Tennessee, United States
Tennessee Oncology PLLC
🇺🇸Smyrna, Tennessee, United States
ICON Cancer Care
🇦🇺South Brisbane, Queensland, Australia
Mater Adult Hospital
🇦🇺South Brisbane, Queensland, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Victoria Breast and Oncology Care
🇦🇺East Melbourne, Victoria, Australia
Barwon Health, University Hospital Geelong
🇦🇺Geelong, Victoria, Australia
Koo Foundation Sun Yat-Sen Cancer Center
🇨🇳Taipei, Taiwan